Advances in bispecific biotherapeutics for the treatment of cancer

Biochemical Pharmacology

Volumn 84, Issue 9, 2012, Pages 1105-1112

  May, Chad ^a   Sapra, Puja ^a   Gerber, Hans Peter ^a  

^a PFIZER INC   (United States)

Author keywords

Anticancer; IgG Bispecific; Immunoglobin; Monoclonal antibody

Indexed keywords

AFM 13; ANTI CD22 ANTIBODY; ANTIBODY; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN; CATUMAXOMAB; CD16 ANTIGEN; CD20 ANTIBODY; CD64 ANTIGEN; CVX 241; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERTUMAXOMAB; FBT A05; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ANTIBODY; IMP 288; IPILIMUMAB; MEHD 7945A; MM 111; MONOCLONAL ANTIBODY; MT 110; MT 111; OZORALIZUMAB; RITUXIMAB; SAR 156597; TF 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CANCER THERAPY; CD3+ T LYMPHOCYTE; CELL FUNCTION; CELL KILLING; CELL MIGRATION; CROSS LINKING; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DOWN REGULATION; DRUG BINDING; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HLA SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; MOLECULAR DOCKING; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RECURRENCE FREE SURVIVAL; REGRESSION ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 84866596013     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.07.011     Document Type: Note

References (60)

1. R.G. Cotton, and C. Milstein Letter: fusion of two immunoglobulin- producing myeloma cells Nature 244 1973 42 43
2. A.M. Scott, J.D. Wolchok, and L.J. Old Antibody therapy of cancer Nat Rev Cancer 12 2012 278 287
3. X. Jimenez, D. Lu, L. Brennan, K. Persaud, M. Liu, and H. Miao A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3 Mol Cancer Ther 4 2005 427 434
4. D. Lu, H. Zhang, D. Ludwig, A. Persaud, X. Jimenez, and D. Burtrum Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody J Biol Chem 279 2004 2856 2865
5. D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes, and M. Prewett A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity J Biol Chem 280 2005 19665 19672
6. Z. Qu, D.M. Goldenberg, T.M. Cardillo, V. Shi, H.J. Hansen, and C.H. Chang Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action Blood 111 2008 2211 2219
7. G. Schaefer, L. Haber, L.M. Crocker, S. Shia, L. Shao, and D. Dowbenko A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies Cancer Cell 20 2011 472 486
8. C.F. McDonagh, A. Huhalov, B.D. Harms, S. Adams, V. Paragas, and S. Oyama Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 Mol Cancer Ther 11 2012 582 593
9. E.A. Rossi, D.M. Goldenberg, T.M. Cardillo, W.J. McBride, R.M. Sharkey, and C.H. Chang Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting Proc Natl Acad Sci USA 103 2006 6841 6846
10. R.M. Sharkey, E.A. Rossi, W.J. McBride, C.H. Chang, and D.M. Goldenberg Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy Semin Nucl Med 40 2010 190 203
11. M.K. Robinson, K.M. Hodge, E. Horak, A.L. Sundberg, M. Russeva, and C.C. Shaller Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro Br J Cancer 99 2008 1415 1425
12. S. Metz, A.K. Haas, K. Daub, R. Croasdale, J. Stracke, and W. Lau Bispecific digoxigenin-binding antibodies for targeted payload delivery Proc Natl Acad Sci USA 108 2011 8194 8199
13. R. Repp, H.H. van Ojik, T. Valerius, G. Groenewegen, G. Wieland, and C. Oetzel Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer Br J Cancer 89 2003 2234 2243
14. M.G. Fury, A. Lipton, K.M. Smith, C.B. Winston, and D.G. Pfister A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors Cancer Immunol Immunother 57 2008 155 163
15. F. Hartmann, C. Renner, W. Jung, C. Deisting, M. Juwana, and B. Eichentopf Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody Blood 89 1997 2042 2047
16. F. Hartmann, C. Renner, W. Jung, L. da Costa, S. Tembrink, and G. Held Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines Clin Cancer Res 7 2001 1873 1881
17. U.D. Staerz, O. Kanagawa, and M.J. Bevan Hybrid antibodies can target sites for attack by T cells Nature 314 1985 628 631
18. P. Perez, R.W. Hoffman, S. Shaw, J.A. Bluestone, and D.M. Segal Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody Nature 316 1985 354 356
19. K. Tanaka, K.J. Isselbacher, G. Khoury, and G. Jay Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene Science 228 1985 26 30
20. U.D. Staerz, and M.J. Bevan Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity Proc Natl Acad Sci USA 83 1986 1453 1457
21. P. Kufer, R. Lutterbuse, and P.A. Baeuerle A revival of bispecific antibodies Trends Biotechnol 22 2004 238 244
22. H. Lindhofer, R. Mocikat, B. Steipe, and S. Thierfelder Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies J Immunol 155 1995 219 225
23. R. Linke, A. Klein, and D. Seimetz Catumaxomab: clinical development and future directions MAbs 2 2010 129 136
24. M. Jager, A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2 Cancer Res 69 2009 4270 4276
25. P. Chames, and D. Baty Bispecific antibodies for cancer therapy: the light at the end of the tunnel MAbs 1 2009 539 547
26. M. Jager, A. Schoberth, P. Ruf, J. Hess, M. Hennig, and B. Schmalfeldt Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) Cancer Res 72 2012 24 32
27. P.A. Baeuerle, and C. Reinhardt Bispecific T-cell engaging antibodies for cancer therapy Cancer Res 69 2009 4941 4944
28. S. Offner, R. Hofmeister, A. Romaniuk, P. Kufer, and P.A. Baeuerle Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells Mol Immunol 43 2006 763 771
29. M.A. Purbhoo, D.J. Irvine, J.B. Huppa, and M.M. Davis T cell killing does not require the formation of a stable mature immunological synapse Nat Immunol 5 2004 524 530
30. T. Dreier, P.A. Baeuerle, I. Fichtner, M. Grun, B. Schlereth, and G. Lorenczewski T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct J Immunol 170 2003 4397 4402
31. K. Brischwein, B. Schlereth, B. Guller, C. Steiger, A. Wolf, and R. Lutterbuese MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors Mol Immunol 43 2006 1129 1143
32. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, and S. Knop Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 2008 974 977
33. D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, and I. Royston IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 1997 3266 3274
34. M.S. Topp, P. Kufer, N. Gokbuget, M. Goebeler, M. Klinger, and S. Neumann Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival J Clin Oncol 29 2011 2493 2498
35. S. Johnson, S. Burke, L. Huang, S. Gorlatov, H. Li, and W. Wang Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion J Mol Biol 399 2010 436 449
36. P.A. Moore, W. Zhang, G.J. Rainey, S. Burke, H. Li, and L. Huang Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma Blood 117 2011 4542 4551
37. P. Strop, W.S. Ho, L.M. Boustany, Y.N. Abdiche, K.C. Lindquist, and S.E. Farias Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair J Mol. Biol 420 2012 204 219
38. N. Liddy, G. Bossi, K.J. Adams, A. Lissina, T.M. Mahon, and N.J. Hassan Monoclonal TCR-redirected tumor cell killing Nat Med 18 2012 980 987
39. Hassan N, Linette G, Carreno B, Kalos M, Harper J, Bossi G, et al. IMCgp100: a novel bi-specific biologic for the treatment of malignant melanoma. AACR 2012 meeting 2012 [abstract # 3525].
40. L. Arnould, M. Gelly, F. Penault-Llorca, L. Benoit, F. Bonnetain, and C. Migeon Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism Br J Cancer 94 2006 259 267
41. L.G. Presta Molecular engineering and design of therapeutic antibodies Curr Opin Immunol 20 2008 460 470
42. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
43. P. Chames, M. Van Regenmortel, E. Weiss, and D. Baty Therapeutic antibodies: successes, limitations and hopes for the future Br J Pharmacol 157 2009 220 233
44. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
45. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
46. T. Blankenstein, P.G. Coulie, E. Gilboa, and E.M. Jaffee The determinants of tumour immunogenicity Nat Rev Cancer 12 2012 307 313
47. A. Gualberto, and Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies Expert Opin Investig Drugs 21 2012 205 216
48. S. Girish, M. Gupta, B. Wang, D. Lu, I.E. Krop, and C.L. Vogel Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother Pharmacol 69 2012 1229 1240
49. J.F. de Vries, C.M. Zwaan, M. De Bie, J.S. Voerman, M.L. den Boer, and J.J. van Dongen The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells Leukemia 26 2012 255 264
50. K. Brischwein, L. Parr, S. Pflanz, J. Volkland, J. Lumsden, and M. Klinger Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class J Immunother 30 2007 798 807
51. M. Cioffi, J. Dorado, P.A. Baeuerle, and C. Heeschen EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells Clin Cancer Res 18 2012 465 474
52. L. Peng, M.D. Oberst, J. Huang, P. Brohawn, C. Morehouse, and K. Lekstrom The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA PLoS ONE 7 2012 e36412
53. S.O. Arnett, J.L. Teillaud, T. Wurch, J.M. Reichert, C. Dunlop, and M. Huber IBC's 21st annual antibody engineering and 8th annual antibody therapeutics international conferences and 2010 annual meeting of the antibody society December 5-9, 2010, San Diego, CA, USA MAbs 3 2011 133 152
54. F. Kratz, and B. Elsadek Clinical impact of serum proteins on drug delivery J Control Release 161 2012 429 445
55. P. Jasinski, P. Zwolak, R. Isaksson Vogel, V. Bodempudi, K. Terai, and J. Galvez MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis Invest New Drugs 29 2011 846 852
56. T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann, U. Syring, and F. Hanakam Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 2002 690 697
57. M. Amann, K. Brischwein, P. Lutterbuese, L. Parr, L. Petersen, and G. Lorenczewski Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3 Cancer Res 68 2008 143 151
58. P. Hoffmann, R. Hofmeister, K. Brischwein, C. Brandl, S. Crommer, and R. Bargou Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 2005 98 104
59. M. Molhoj, S. Crommer, K. Brischwein, D. Rau, M. Sriskandarajah, and P. Hoffmann CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis Mol Immunol 44 2007 1935 1943
60. R. Lutterbuese, T. Raum, R. Kischel, P. Hoffmann, S. Mangold, and B. Rattel T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells Proc Natl Acad Sci USA 107 2010 12605 12610